Herpes Infection Treatment Market

The Herpes Infection Treatment Market is valued at USD 2.5 Bn in 2026 and is projected to reach USD 3.9 Bn, growing at a CAGR of 7% by 2033.

Increasing Awareness Regarding Herpes Infection to Fortify Herpes Infection Treatment Market

The rise in herpes infection prevalence, and public knowledge of the condition are both factors contributing to the herpes infection treatment market expansion. For instance, the WHO estimates that almost 50 million individuals worldwide will have genital herpes in 2020, brought on by type 1 or type 2 of the herpes simplex virus HSV, and several billion people will have oral infections. The asymptomatic aspect of the illness increases its transmission rate, opening up a market for therapies. The prevalence of ailments like diabetes and hypertension and a rise in the adoption of unhygienic practices in developing and underdeveloped nations are anticipated to impact  market revenue growth positively. The expansion of R&D initiatives is another factor in the industry. Due to the significant financial burden that herpes simplex virus infections place on healthcare systems worldwide, there is a largely untapped market for treating these infections. This herpes infection treatment market growth is anticipated to be aided by massive investments in the research and development of efficient therapeutics.

For instance, in February 2021, the Federal Ministry of Education and Research (BMBF) awarded Dr. Florian Full at the Institute of Clinical and Molecular Virology at Universitätsklinkum Erlangen at Friedrich-Alexander-Universität (FAU) funding of EUR 2.34 million for the creation of a novel herpes virus drug. The funding will be available for the following five years. The study's results could have a favorable effect on the herpes infection treatment market and thus accelerate the expansion of the market under investigation. But one of the main things holding back the market expansion is the stigma attached to STDs, which drives product recalls.

Herpes Infection Treatment Market: COVID-19 Impact

Governments worldwide are collaborating with pharmaceutical and biotech businesses to combat the COVID-19 outbreak, from fostering the creation of vaccinations to preparing for issues with the distribution of medical supplies. About 155 compounds and 115 vaccine candidates are now in the R&D pipeline. Additionally, there has been a sharp increase in demand for regularly used medications such as hydroxychloroquine to treat COVID-19. Due to the severe shortage of these medications in many industrialized nations, the extremely high demand for these medications has created enormous potential for the makers of COVID-19 management medications. Thus, the pharmaceutical and biotechnology industry is expected to witness significant growth due to the demand for vaccines and treatment drugs for COVID-19. This is then anticipated to considerably affect the herpes infection treatment market.

Rising Prevalence of Herpes Infection to Boost Herpes Infection Treatment Market

A significant reason driving the increase of the worldwide herpes infection treatment market share is the rising prevalence of herpes infection. Several additional variables have contributed to the increased prevalence of herpes aside from the conventional risk factors like sexual or physical contact with the infected person. Herpes infection is more likely to affect people whose immune systems have been compromised by immunosuppressants taken for organ transplantation. They are a significant contributor to the rising incidence of herpes. It is considered that those with immunocompromised status are more susceptible to contracting this viral illness. Additionally, those who have undergone organ transplants, HIV/AIDS, or both are more likely to get herpes. Herpesvirus infections continue to be a significant cause of mortality and morbidity for a substantial percentage of transplant recipients despite the significant advancements in organ transplantation over the past few decades. These factors will cause the market to develop significantly throughout the forecast period.

Emergence of Advanced Treatment Options to Fuel Herpes Infection Treatment Market

The key factor driving the increase in the global herpes infection treatment market share is the emergence of innovative therapeutics. One of the biggest challenges facing the market is currently facing is a high reliance on a few treatments. For instance, there is currently no cure for oral or genital herpes, the condition can only be controlled with the available treatments. Better treatments are anticipated to come soon, thanks to several trials being tested. The main medications used to treat genital herpes prevent outbreaks but do not prevent shedding. Research is being conducted to create new therapeutic options to get beyond these restrictions. As an illustration, Genocea is creating the GEN-003 vaccine. It is now undergoing clinical testing and has been demonstrated to be successful in reducing HSV-2 infection outbreaks and shedding. Only those already infected with the virus can benefit from the therapeutic effects of GEN-003. Trials to stop the infection are also being thought about. Potentially better illness treatment facilities will result from introducing such innovative treatments.

Highly Generic Herpes Infection Treatment Market to Limit Growth

During the projected period, the market would face significant obstacles due to its high level of genericization. Due to the patent expiration and subsequent launch of generics, the herpes infection treatment market is largely generic. Due to support from numerous governmental and non-governmental groups, the generic  market is achieving deeper market penetration. These generic medications are now more widely used due to their cheaper costs. However, this has increased price competitiveness in the market and reduced the overall revenue produced by the vendors operating in the branded medication market. About 22 European nations and many U.S. states have adopted generic substitution. This was done to boost the distribution of generic medications and drive down the price of pharmaceutical goods. Generic drug substitution has successfully expanded the use of generic medications and reduced the overall growth of personal pharmaceutical costs. Such examples of volume replacing value due to the  market high prevalence of generics continue to be a growth barrier.

Herpes Simplex 1 Category Dominates Herpes Infection Treatment Market

Herpes Simplex 1 category held the largest market share, and it is anticipated that it will continue to rule the market during the forecast period. This can be attributable to the population's rising prevalence of HSV-1 infection. As an illustration, the WHO estimates that 3.7 billion people worldwide over 50 are infected with HSV-1. Additionally, the market is being driven by the rising risk of HSV-1 transmission, which can be contracted through oral-genital contact, contact with infected saliva, sores, or even sores on the skin. Additionally, the segment's expansion is anticipated to be aided by the rising prevalence of Herpes simplex virus-1 encephalitis (HSE), a rare neurological condition brought on by the virus.

Valacyclovir Category to Dominate Herpes Infection Treatment Market Based on Higher Affordability, Accessibility, and Efficacy

The valacyclovir category dominated the herpes infection treatment market in 2021. This is explained by the affordability, accessibility, and efficacy of valacyclovir in preventing the herpes virus from replicating in the body and so assisting in the control of an outbreak's symptoms. Acyclovir is easily broken down by the liver when taken orally, which contributes to the fact that valacyclovir is most frequently used for cold sores due to its higher absorption rate. In addition, research published in the American Journal of Ophthalmology found that valacyclovir 500 mg is just as efficient as acyclovir 800 mg at preventing the recurrence of HSV eye illness. Besides, due to its widespread recognition as the gold standard for treating herpes infection, the medicine acyclovir is anticipated to experience the fastest increase during the projection period. According to statistics, 3,517,810 acyclovir prescriptions are anticipated to be written in the United States year 2020. The medication serves as a first-line antiviral drugs that are offered in topical, oral, and intravenous formulations, which raises acceptance among the intended audience.

North America to Dominate Herpes Infection Treatment Market due to Rising Healthcare Costs

Over the forecast period, it is anticipated that the North American market will account for the largest revenue share attributed to rising healthcare costs, increased use of branded medications to treat herpes infections, more generic medications, and favorable reimbursement practices. Growing elderly and immunocompromised populations, as well as an increase in illness prevalence, are raising public awareness, which is fueling the herpes infection treatment market expansion. For instance, HSV was one of the most common sexually transmitted illnesses in the United States in 2021, according to the CDC. Major important players are also extending their product portfolios to match the high demand for efficient treatment choices. For instance, Moderna, Inc. added three new development studies to its mRNA pipeline in 2022 to lower the incidence of shingles.

The Asia Pacific market is anticipated to experience stable revenue growth throughout the forecast period. Growing government measures to increase treatment uptake, expanding healthcare infrastructure, and regional expansion of major companies in Asian nations contribute to this region's rise. Additionally, the increasing herpes incidence in developing nations like China and India is anticipated to aid growth. The existence of numerous local players and the resulting fragmented herpes infection treatment market is responsible for the greater adoption rate of generics for treating herpes in the area. The market is expanding due to increased efforts to create a vaccine as a preventive approach to halt the spread of sickness.

Global Herpes Infection Treatment Market: Competitive Landscape

A few of the players in the herpes infection treatment market:

• GlaxoSmithKline plc
• Novartis AG
• F. Hoffmann-La Roche Ltd.
• Merck & Co., Inc.
• Pfizer Inc.
• AbbVie Inc.
• Teva Pharmaceutical Industries Ltd.
• Mylan N.V.
• Sun Pharmaceutical Industries Ltd.
• Dr. Reddy’s Laboratories Ltd.
• Cipla Limited
• Apotex Inc.
• Aurobindo Pharma Limited
• Amneal Pharmaceuticals, Inc.
• Zydus Lifesciences Limited

Global Herpes Infection Treatment Market is Segmented as Below:

By Product

• Therapeutics
• Vaccine

By Type

• Herpes Simplex
• Herpes Simplex 1
• Herpes Simplex 2
• Herpes Zoster

By Drug

• Acyclovir
• Valacyclovir
• Famciclovir
• Others

By Route of Administration

• Oral
• Topical
• Injection

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By Region

• North America
• Europe
• Asia Pacific
• LAMEA